Thiogenesis Therapeutics Corp (TSE:TTI) has released an update.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Thiogenesis Therapeutics Corp has secured a key European patent for its innovative thiol compounds, enhancing its global intellectual property portfolio. The patent supports the company’s lead compound, TTI-0102, which aims to combat oxidative stress, a factor in chronic diseases like mitochondrial disorders and diabetes.
For further insights into TSE:TTI stock, check out TipRanks’ Stock Analysis page.
Trending Articles:
Looking for a trading platform? Check out TipRanks' Best Online Brokers guide, and find the ideal broker for your trades.
Report an Issue